|
Acorda Therapeutics hopes its products really get on your nerves. The company is developing therapeutics that aim to restore neurological function for patients with spinal cord injury and other central nervous system disorders. The company markets and sells muscle relaxant Zanaflex in the US. Its lead drug development candidate is Fampridine-SR, which enhances conduction in the myelin layer of nerves damaged by blunt trauma or from multiple sclerosis (MS). The drug uses a sustained-release delivery system developed by and licensed from Elan Corporation. Acorda's other drug candidates include potential therapies for MS, brain damage, and spinal cord injuries.
|
| | | Contact Information | |
Address: |
15 Skyline Dr.
Hawthorne, NY 10532
| | Phone: | 914-347-4300 | | Fax: | 914-347-4560 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 47.80 M | | Revenue Growth (1 yr): | 21.10% | | Employees (2008): | 174 | | Employee Growth (1 yr): | 20.80% |
|
|
Key People
| | • |
President CEO, and Director:
Ron Cohen
| | • |
CFO:
David Lawrence
| | • |
VP Business Development:
Ruhi Khan
|
|
|
